Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?
- PMID: 26413426
- PMCID: PMC4583055
- DOI: 10.1080/21623996.2015.1071000
Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?
Abstract
Lentiginoses is a clinical feature in which lentigines are remarkably present in large numbers or when they occur in a distinctive distribution on apparently normal skin. This entity may be congenital or acquired and may cover a wide spectrum of diseases ranging from an isolated benign pigmentary disorder to numerous syndromes associated with molecular abnormalities.We present a 59-year-old female patient with multiple lentigines which first emerged 3 y ago concurrently with policytemia vera. The patient had found to be positive for Janus Kinase-2 (JAK-2) mutation. Over activation of the pathway due to JAK-2 V617F mutation is a well-known condition in myeloproliferative diseases but has not been reported in melanocytic disorders. Moreover, several signaling pathways have previously been defined with lentiginosis except JAK-STAT pathway. We want to draw attention to the potential effect of JAK-2 mutation in lentigogenesis with this case report.
Keywords: Janus-kinase 2; Polycythemia vera; lentiginosis; tyrosine kinase.
Figures





Similar articles
-
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA. Arch Pathol Lab Med. 2014. PMID: 25171702
-
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Orv Hetil. 2011. PMID: 22011365 Hungarian.
-
[Myeloproliferative diseases caused by JAK2 mutation].Rinsho Byori. 2009 Apr;57(4):357-64. Rinsho Byori. 2009. PMID: 19489438 Review. Japanese.
-
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.Cancer Genet Cytogenet. 2009 Feb;189(1):43-7. doi: 10.1016/j.cancergencyto.2008.09.010. Cancer Genet Cytogenet. 2009. PMID: 19167611 Review.
-
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.J Exp Clin Cancer Res. 2019 Feb 4;38(1):49. doi: 10.1186/s13046-019-1062-x. J Exp Clin Cancer Res. 2019. PMID: 30717771 Free PMC article.
References
-
- Bishop JA. Lentigos, Melanocytic Naevi and Melanoma In: Burns T, Breathnach S, Cox N, Griffiths N, eds. Rook's textbook of Dermatology. Wiley-Blackwell, 2010:1-5
-
- Bauer AJ, Stratakis CA. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet 2005; 42:801-10; PMID:15958502; http://dx.doi.org/10.1136/jmg.2003.017806 - DOI - PMC - PubMed
-
- Santoro C, Pacileo G, Limongelli G, Scianguetta S, Giugliano T, Piluso G, Ragione FD, Cirillo M, Mirone G, Perrotta S. LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies. BMC Med Genet 2014; 15:44; PMID:24767283; http://dx.doi.org/10.1186/1471-2350-15-44 - DOI - PMC - PubMed
-
- Kim MS, Youn SH, Na CH, Kim JK, Shin BS. Generalized eruptive lentiginosis in a healthy elderly man. Ann Dermatol 2014; 26:649-50; PMID:25324666; http://dx.doi.org/10.5021/ad.2014.26.5.649 - DOI - PMC - PubMed
-
- Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011; 10:481-90; PMID:21538076; http://dx.doi.org/10.1007/s10689-011-9446-x - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous